amivantamab + leucovorin + fluorouracil + oxaliplatin

This drug is a combination regimen consisting of **amivantamab**, **leucovorin** (also known as folinic acid), **fluorouracil**, and **oxaliplatin**. - **Amivantamab** is a bispecific monoclonal antibody targeting both **epidermal growth factor receptor (EGFR)** and **mesenchymal-epithelial transition (MET) receptor**. By binding to the extracellular domains of these receptors, amivantamab inhibits ligand binding, enhances receptor degradation, and facilitates immune-mediated cytotoxicity through mechanisms such as antibody-dependent cellular cytotoxicity and trogocytosis[3][5]. - **Leucovorin** is a reduced form of folic acid that enhances the binding of fluorouracil to the enzyme thymidylate synthase, thereby potentiating its antineoplastic effects[2][6]. - **Fluorouracil** (5-FU) is a pyrimidine analog and antimetabolite that inhibits thymidylate synthase, interfering with DNA and RNA synthesis and function[2][4][6]. - **Oxaliplatin** is a platinum-based chemotherapeutic that forms DNA adducts, damaging DNA and leading to apoptosis of cancer cells[2][4][6]. This combination is not a standard or widely referenced regimen in current clinical practice but is comprised of distinct, approved agents in oncology. **FOLFOX** (leucovorin + fluorouracil + oxaliplatin) is a standard regimen for colorectal and other gastrointestinal cancers, and amivantamab is approved for NSCLC in combination with platinum-based chemotherapy but not typically with FOLFOX components[1][2][3][4][5][6]. The mechanisms allow for targeting both signal transduction pathways (EGFR, MET) and cytotoxic activity against rapidly dividing cells.

Other names

folfox + amivantamab